HDL-C and LDL-C: Their role in stroke pathogenesis and implications for treatment

Current Treatment Options in Cardiovascular Medicine

Volumn 10, Issue 3, 2008, Pages 195-206

  Sanossian, Nerses ^a   Tarlov, Nicholas E ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESTIPOL; COLESTYRAMINE; D 4F; ESTROGEN; ETC 216; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONG ACTING DRUG; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PROSTAGLANDIN D2 INHIBITOR; PROSTAGLANDIN INHIBITOR; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIETARY INTAKE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; FLUSHING; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIVER FUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; LOW FAT DIET; MENOPAUSE; MONOTHERAPY; NONHUMAN; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; RETINA MACULA EDEMA; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SIDE EFFECT; SMOKING CESSATION; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION;

EID: 56349149980     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-008-0021-1     Document Type: Review

References (53)

1. American Heart Association: 2004 heart and stroke statistical update. Available at http://www.Americanheart.Org/statistics/ index.html. Accessed November 2004.
2. Sanossian N, Ovbiagele B: Multimodality stroke prevention. Neurologist 2006, 12:14-31.
3. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995, 346:1647-1653.
4. Sacco RL, Benson RT, Kargman DE, et al.: High-flensity lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001, 285:2729-2735.
5. Shahar E, Chambless LE, Rosamond WD, et al.: Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2003, 34:623-631.
6. Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, et al.: High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med 2003, 163:1549-1554.
7. Wannamethee SG, Shaper AG, Ebrahim S: HDL-Cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke 2000, 31:1882-1888.
8. Suk S-H, Sacco RL, Boden-Albala B, et al.: Abdominal obesity and risk of ischemic stroke: the Northern Manhattan Stroke Study. Stroke 2003, 34:1586-1592.
9. Hooper L, Griffiths E, Abrahams B, et al.: Dietetic guidelines: diet in secondary prevention of cardiovascular disease (first 1update, June 2003). J Hum Nutr Diet 2004, 17:337-349.
10. Krauss RM, Eckel RH, Howard B, et al.: AHA Dietary Guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Stroke 2000, 31:2751-2766.
11. King AC, Haskell WL, Young DR, et al.: Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation 1995, 91:2596-2604.
12. Maeda K, Noguchi Y, Fukui T: The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 2003, 37:283-290.
13. Dattilo AM, Kris-Etherton PM: Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992, 56:320-328.
14. Ellison RC, Zhang Y, Qureshi MM, et al.: Investigators of the NHLBI Family Heart Study: Lifestyle determinants of high-density lipoprotein cholesterol: the national heart, lung, and blood institute family heart study. Am Heart J 2004, 147:529-535.
15. Joshipura KJ, Ascherio A, Manson JE, et al.: Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA 1999, 282:1233-1239.
16. Gerasimova E, Perova N, Ozerova I, et al.: The effect of dietary n-3 polyunsaturated fatty acids on HDL cholesterol in Chukot residents vs muscovites. Lipids 1991, 26:261-265.
17. Meksawan K, Pendergast DR, Leddy JJ, et al.: Effect of low and high fat diets on nutrient intakes and selected cardiovascular risk factors in sedentary men and women. J Am Coll Nutr 2004, 23:131-140.
18. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999, 341:498-511.
19. Corvol J-C, Bouzamondo A, Sirol M, et al.: Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med 2003, 163:669-676.
20. Amarenco P, Labreuche J, Lavallee P, Touboul PJ: Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004, 35:2902-2909.
21. Furberg C, Adams HP Jr, Applegate WB, et al.: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) research group. Circulation 1994, 90:1679-1687.
22. Heart Protection Study Collaborative Group: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004, 363:757-767.
23. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al.: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549-559.
24. Amarenco P, Goldstein LB, Szarek M, et al.: Lipoprotein, blood pressure and stroke risk: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study [abstract]. Neurology 2007, 68:A208.
25. Sanossian N, Saver JL, Navab M, Ovbiagele B: High-density lipoprotein cholesterol: an emerging target for stroke treatment. Stroke 2007, 38:1104-1109.
26. Bloomfield HE: The role of fibrates in a statin world. Arch Intern Med 2006, 166:715-716.
27. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
28. Bloomfield Rubins H, Davenport J, Babikian V, et al.: Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001, 103:2828-2833.
29. Haffner SM; American Diabetes Association: Dyslipidemia management in adults with diabetes. Diabetes Care 2004, 27(Suppl 1):68S-S71.
30. Elam MB, Hunninghake DB, Davis KB, et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000, 284:1263-1270.
31. Meyers CD, Kamanna VS, Kashyap ML: Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004, 15:659-665.
32. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al.: Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990, 264:3013-3017.
33. Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
34. Brown BG, Zhao X-Q, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
35. Taylor AJ, Sullenberger LE, Lee HJ, et al.: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. Circulation 2004, 110:3512-3517.
36. Whitney EJ, Krasuski RA, Personius BE, et al.: A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005, 142:95-104.
37. Stroke Council, American Heart Association; American Stroke Association: Statins after ischemic stroke and transient ischemic attack: an advisory statement from the Stroke Council, American Heart Association and American Stroke Association. Stroke 2004, 35:1023.
38. Grundy SM, Cleeman JI, Merz CNB, et al., for the Coordinating Committee of the National Cholesterol Education Program, Endorsed by the National Heart Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
39. Brousseau ME, Schaefer EJ, Wolfe ML, et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505-1515.
40. Barter PJ, Caulfield M, Eriksson M, et al.: the ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
41. Franceschini G, Sirtori CR, Capurso A, et al.: A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980, 66:892-900.
42. Shah PK, Nilsson J, Kaul S, et al.: Effects of recombinant apolipoprotein A-IMilano on aortic atherosclerosis in apolipoprotein e-deficient mice. Circulation 1998, 97:780-785.
43. Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
44. Navab M, Anantharamaiah GM, Reddy ST, et al.: Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005, 25:1325-1331.
45. Navab M, Anantharamaiah GM, Hama S, et al.: Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002, 105:290-292.
46. Khan M, Perez A, Goldberg R, et al.: Subanalysis of the comparative effects of pioglitazone and rosiglitazone on markers of diabetic dyslipidemia in elderly patients with type 2 diabetes and dyslipidemia [abstract]. Endocr Pract 2006, 12:18-19.
47. IRIS: Insulin Resistance Intervention after Stroke Trial. Available at http://www.Iristrial.org/. Accessed February 2008.
48. Fogelman AM: When good cholesterol goes bad. Nat Med 2004, 10:902-903.
49. Schulman KA, Kinosian B, Jacobson TA, et al.: Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA 1990, 264:3025-3033.
50. Lachaine J, Merikle E, Tarride J-E, et al.: A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets. Clin Ther 2007, 29:519-528.
51. Roze S, Ferrieres J, Bruckert E, et al.: Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective. Int J Clin Pract 2007, 61:1805-1811.
52. Waters DD, LaRosa JC, Barter P, et al.: Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study. J Am Coll Cardiol 2006, 48:1793-1799.
53. Sacks FM, Handysides GH, Marais GE, et al.: Effects of a low-fat diet on plasma lipoprotein levels. Arch Intern Med 1986, 146:1573-1577.